Rakovina Therapeutics Inc. reported a net loss of $2.9 million for Q2 2025, with R&D expenses at $1.6 million and G&A expenses at $1.2 million. The company closed a private placement of 7.1 million equity units for gross proceeds of $3.56 million. They also implemented a 1-for-10 share consolidation. Subsequent events include intentions to amend outstanding warrants and convertible debentures. Financial results show cash and cash equivalents at $1.88 million as of June 30, 2025, and a net loss of $2.9 million for the quarter. The company focuses on developing cancer treatments using AI-powered drug discovery technologies.

Read more at GlobeNewswire: Rakovina Therapeutics Announces Three-Month Q2 ended June